Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + RT +/- Olaparib in Metastatic TNBC or ER+/HER2- Breast Cancer
NCT04683679Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Apr 2021
- Primary completion
- Jan 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, olaparib in triple-negative breast cancer (TNBC), estrogen receptor-positive breast cancer (ER+), sponsored by Memorial Sloan Kettering Cancer Center. Started Apr 2021; status: recruiting.
02
Drugs
pembrolizumabolaparib
03
Conditions
triple-negative breast cancer (TNBC)estrogen receptor-positive breast cancer (ER+)
Beyond the preview
Go deeper on NCT04683679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04683679.